This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC).

We are pleased to announce that the pharmaceutical Joint Rapid Assessment on “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)” is now available. The final assessment report was published in January 2018. Find the documentation provided by the authoring team here.